Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
IntroductionDiscontinuation of tyrosine kinase inhibitor (TKI) treatment is emerging as the main therapy goal for Chronic Myeloid Leukemia (CML) patients.The DESTINY trial showed that TKI dose reduction prior to cessation can lead to an increased number of patients achieving sustained treatment free remission (TFR).However, there has been no system